On July 2, 2025, MIRA Pharmaceuticals reported that its drug candidate Mira-55 provides pain relief comparable to morphine, without the side effects of opioids, and confirmed its legal status as a non-controlled substance. The company also progressed with the acquisition of SKNY Pharmaceuticals, which has shown potential in obesity and nicotine addiction treatment.